(Albany, US) DelveInsight launched its new report on Pulmonary Arterial Hypertension (PAH) – Market Insights, Epidemiology, and Market Forecast-2030
DelveInsight’s “Pulmonary Arterial Hypertension (PAH) – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Pulmonary Arterial Hypertension (PAH) , historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension (PAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the report:1. Pulmonary Arterial Hypertension (PAH) prevalence was observed to be 109 per million individuals among the population of fewer than 65 years old.2. Around 16.2% of patients are newly diagnosed with Pulmonary Arterial Hypertension.3. The overall prevalence of Pulmonary Hypertension was found to be 19.2 cases per Million Adult Inhabitants (MAI) among the Spanish population.
Key benefits of the report:1. Pulmonary Arterial Hypertension market report covers a descriptive overview and comprehensive insight of the Pulmonary Arterial Hypertension Epidemiology and Pulmonary Arterial Hypertension market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Pulmonary Arterial Hypertension market report provides insights into the current and emerging therapies.3. Pulmonary Arterial Hypertension market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Pulmonary Arterial Hypertension market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Pulmonary Arterial Hypertension market.
Download free sample pages: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market
“In 2017 the total prevalent cases of Pulmonary Arterial Hypertension were 70,774 in the seven major markets.”
The key players in Pulmonary Arterial Hypertension market are:1. United Therapeutics2. Liquidia Technologies3. Reata Pharmaceuticals4. Altavant Sciences5. Acceleron Pharma
The launch of the emerging therapies is expected to significantly impact Pulmonary Arterial Hypertension treatment scenario in the upcoming years:-Drugs covered:1. Aurora-GT2. Ralinepag3. Bardoxolone Methyl4. Rodatristat Ethyl5. Sotatercept
Table of contents:
1. Key Insights2. Executive Summary of Pulmonary Arterial Hypertension3. SWOT Analysis of Pulmonary Arterial Hypertension4. Pulmonary Arterial Hypertension Market Overview at a Glance5. Pulmonary Arterial Hypertension Disease Background and Overview6. Pulmonary Arterial Hypertension Epidemiology and Patient Population7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)7.1. The United States7.2. Germany7.3. France7.4. Italy7.5. Spain7.6. The United Kingdom7.7. Japan8. Pulmonary Arterial Hypertension Treatment Algorithm9. Unmet Needs10. Case Studies11. Organizations related to Pulmonary Arterial Hypertension12. Pulmonary Arterial Hypertension Marketed Drugs12.1.Approval and Market Presence13. Pulmonary Arterial Hypertension Marketed Drugs by Companies13.1.United Therapeutics Corporation13.2.Johnson & Johnson13.3.GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.13.4.Bayer AG13.5. Pfizer14. Safety and Efficacy of Marketed Drugs15. Pulmonary Arterial Hypertension Emerging Therapies15.1. Emerging Drugs Analysis15.2.Aurora-GT: United Therapeutics15.3.Ralinepag: United Therapeutics15.5.Bardoxolone Methyl: Reata Pharmaceuticals15.6.Rodatristat Ethyl: Altavant Sciences15.7. Sotatercept: Acceleron Pharma15.8. PB1064: PhaseBio Pharmaceuticals15.9. CXA-10: Complexa16. Other Promising Candidates16.1. Inhaled Nitric Oxide: Bellerophon Pulse Technologies16.2.RT234: Respira Therapeutics17. Pulmonary Arterial Hypertension 7 Major Market Analysis18. United States19. EU5 Countries19.1.Germany19.2. France19.3. Italy19.4. Spain19.5.United Kingdom20. Japan21. Market Drivers22. Market Barriers23. Appendix24. DelveInsight Capabilities25. Disclaimer26. About DelveInsight
Download free report on Pulmonary Arterial Hypertension @https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market
Related reports:
Pulmonary Arterial Hypertension – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020
Persistent Pulmonary Hypertension of the Newborn – Market Insights, Epidemiology, and Market Forecast-2030
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/